NASDAQ:LEXX Lexaria Bioscience Q1 2025 Earnings Report $3.28 -0.09 (-2.67%) Closing price 04:00 PM EasternExtended Trading$3.32 +0.04 (+1.07%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Lexaria Bioscience EPS ResultsActual EPS-$2.40Consensus EPS -$1.80Beat/MissMissed by -$0.60One Year Ago EPSN/ALexaria Bioscience Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ALexaria Bioscience Announcement DetailsQuarterQ1 2025Date1/10/2025TimeN/AConference Call DateFriday, January 10, 2025Conference Call Time7:00AM ETUpcoming EarningsLexaria Bioscience's Q4 2026 earnings is estimated for Wednesday, October 28, 2026, based on past reporting schedulesConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Lexaria Bioscience Earnings HeadlinesTalphera (NASDAQ:TLPH) versus Lexaria Bioscience (NASDAQ:LEXX) Head to Head ContrastSeptember 24 at 4:44 AM | americanbankingnews.comLexaria Bioscience Corp.: Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross ProceedsSeptember 9, 2026 | finanznachrichten.deMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.September 25 at 1:00 AM | The Oxford Club (Ad)LEXX: Introducing DehydraTECH 3.0September 8, 2026 | finance.yahoo.comLexaria Bioscience advances 12% on Australian tax rebateSeptember 1, 2026 | seekingalpha.comLexaria receives $2.6M R&D tax rebate from Australian Tax Office; shares up over 14%September 1, 2026 | msn.comSee More Lexaria Bioscience Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lexaria Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lexaria Bioscience and other key companies, straight to your email. Email Address About Lexaria BioscienceLexaria Bioscience (NASDAQ:LEXX) is a biotechnology company developing drug-delivery technologies designed to improve the absorption and delivery of orally administered active compounds. Its proprietary DehydraTECH platform is intended to enhance bioavailability and may facilitate the delivery of certain compounds across biological barriers, including the blood-brain barrier. The company has researched DehydraTECH applications involving cannabinoids, nicotine, non-steroidal anti-inflammatory drugs, antiviral compounds and other active pharmaceutical ingredients. Lexaria’s work includes laboratory studies, formulation development and human clinical research intended to evaluate the platform’s potential for pharmaceutical, nutraceutical and consumer-health products. Founded in Canada, Lexaria is headquartered in Kelowna, British Columbia, and conducts research and development activities for potential applications in international markets. The company has historically pursued commercialization through product development, licensing and partnerships, while retaining a focus on advancing DehydraTECH as a broadly applicable drug-delivery platform. Lexaria is led by Chief Executive Officer Chris Bunka.View Lexaria Bioscience ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Space Stocks to Watch as SpaceX Reshapes the Launch MarketOil May Be Stronger Than It Looks—And Diamondback Is on SaleBlackBerry Shifts Gears With Coretura Deal Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
